Xconomy: Cardeas Gears Up for Clinic, With Drug Combo for Hospital Infections
Summary
The plan here is to combine the two antibiotics in an aerosol form, give them in about one-tenth the usual dose, but deliver it where it needs to go deep in the lungs with a nebulizer that’s modified to work with mechanical ventilators, Montgomery says.The nebulizer that Cardeas is using is a modified form of the Pari e-Flow device that Montgomery and his team used before to develop aztreonam lysine (Cayston) to fight lung infections in cystic fibrosis patients.The Cardeas drugs will likely be given in combination with intravenous antibiotics that circulate throughout the bloodstream, which have a better chance of killing infectious bugs outside the lungs, Montgomery says.While the main goal of this initial phase study will be to assess safety and tolerability, Cardeas will also be able to measure how much of its antibiotics are getting into sputum secretions from the lungs, which offers a hint of whether the drug has a good chance of clearing future efficacy hurdles.But even though it’s still years from getting that far, much less into negotiations with health insurers over reimbursement, Montgomery says he’s picked this program partly because it shouldn’t have a problem getting paid for it.
Classifications
AskAI Classifications
LabelsLinked Companies
